Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic Alpha Clinic Contact Trial Sponsor Disease Indication Clinical Trial Name Status of Enrollmentsort ascending Learn More
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Long-Term Follow-up Study for Patients Previously Treated With JCAR015 No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Stroke Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
jCyte Eye - Retinitis Pigmentosa (RP) Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) No longer active
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Active, not recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Longeveron Aging frailty Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements Active, not recruiting
UCI
& UC Davis
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
UC Davis: Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Humacyte Kidney Failure An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) Active, not recruiting
UCLA
& UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu
UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) Active, not recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
Orchard Therapeutics Severe Combined Immunodeficiency (SCID) Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency Active, not recruiting
City of Hope
Joseph Rosenthal, MD
626-256-4673 ext 88442
jrosenthal@coh.org
City of Hope Sickle Cell Disease Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
newing@coh.org
Sangamo Therapeutics Hemophilia A Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children's Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Adaptimmune Cancer - Myeloma NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
City of Hope
Alex Herrera, MD
626-218-2405
aherrera@coh.org
Kite Pharma Cancer - Lymphoma Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
City of Hope
Leslie Popplewell, MD
626-218-2405
lpopplew@coh.org
Novartis Pharmaceuticals Cancer - Lymphona Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Elizabeth Budde, MD
626-218-2405
Kite Pharma Cancer - Lymphoma A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
City of Hope
Karen Reckamp, MD
626-218-9200
kreckamp@coh.org
Glaxo Smith Kline (GSK) Cancer - Lung Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Recruiting
City of Hope
Myo Htut, MD
626-218-2405
mhtut@coh.org
Janssen Research & Development, LLC. Cancer - Myeloma A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) Recruiting
City of Hope
Elizabeth Budde, MD, PhD
626-218-2405
ebudde@coh.org
City of Hope Cancer - Lymphoma Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
​newing@coh.org
Sangamo Therapeutics Hemophilia B Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B Recruiting
City of Hope
Teresa Kim
626-218-0263
teresakim@coh.org
City of Hope Sickle Cell Disease A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Recruiting
City of Hope
Tanya Dorff, MD
626-218-9200
tdorff@coh.org
City of Hope Cancer - Prostate PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Lymphoma Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
City of Hope
Cara Nolan
626-218-3241
canolan@coh.org
Juno Therapeutics Cancer - Lymphoma An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting
City of Hope
Erminia Massarelli, MD
626-218-9200
emassarelli@coh.org
Atara Bio. Cancer - Nasopharyngeal Carcinoma Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Recruiting
City of Hope
Mihaela Cristea, MD
626-218-9200
mcristea@coh.org
Torque Therapeutics, Inc. Cancer - Lymphoma TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas Recruiting
City of Hope
Lucy Ghoda
626-218-3605
lghoda@coh.org
City of Hope Neurodegenerative Disorder Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) Recruiting

Pages

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News